RWA
GHDX

Redhawk Wealth Advisors’s Genomic Health, Inc. GHDX Stock Holding History

Redhawk Wealth Advisors’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,580
Closed -$391K – 502
2019
Q1 		$391K Buy
+5,580
New +$414K 0.21% 81

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Redhawk Wealth Advisors's GHDX Position: Q2 2019 in Review

Redhawk Wealth Advisors sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 5,580 shares — an estimated $391K sold.

Redhawk Wealth Advisors first reported a position in GHDX in Q1 2019 and held it in 1 quarter. The position peaked at $391K in Q1 2019. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

  • Redhawk Wealth Advisors reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
  • Redhawk Wealth Advisors sold 5,580 Genomic Health, Inc. shares in Q2 2019, an estimated $391K.
  • Redhawk Wealth Advisors first reported a position in Genomic Health, Inc. in Q1 2019 and held it in 1 quarter.
  • Redhawk Wealth Advisors's Genomic Health, Inc. position peaked at $391K in Q1 2019.
  • 215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on Redhawk Wealth Advisors's 13F filing for Q2 2019, filed 9 Aug 2019.